| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PHA-793887 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.2 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | -0.064 | 0.2 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.044 | 0.2 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | BRD9876 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | BRD-K27188169 | CTRPv2 | pan-cancer | AAC | 0.065 | 0.2 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.04 | 0.2 |
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.038 | 0.2 |